<DOC>
	<DOCNO>NCT00448357</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , fludarabine busulfan , donor peripheral stem cell transplant help stop growth cancer abnormal cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving monoclonal antibody , alemtuzumab , transplant tacrolimus transplant may stop happen . PURPOSE : The phase I portion trial identify maximum tolerated dose busulfan treat 40 patient dose-escalation scheme . We treat additional 26 patient phase II portion trial PK-directed dose total AUC 6912 uM-min/24 hour . We transition Phase II portion study October 2009 .</brief_summary>
	<brief_title>Fludarabine PK-Directed Busulfan With Without ATG Followed By Donor Peripheral Stem Cell Transplant Treating Patients With Hematologic Cancer Other Diseases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Phase I Objective : To identify maximum tolerate dose continuous infusion IV busulfan base blood level derive test dose conjunction fludarabine , ATG methotrexate plus tacrolimus GVHD prophylaxis - Phase II Objective : To determine one-year disease-free survival ( DFS ) rate maximum tolerate dose identified Phase I trial ( target AUC 6912 ) Secondary - Determine overall disease-free survival patient treat regimen . - Determine dose-limiting toxicity regimen patient . - Determine capacity test dosing busulfan would result desired area curve concentration exposure patient receive full-dose busulfan regimen . - Determine incidence graft-vs-host disease DNA chimerism 1 month 2 year post-transplantation patient . - Compare overall survival ( OS ) disease-free survival ( DFS ) rate patient treat Campath vs. patient treated ATG/Methotrexate GVHD control OUTLINE : This non-randomized , open-label , parallel group study busulfan . Patients stratify accord donor relationship ( match relate donor [ MRD ] v match unrelated donor [ MUD ] ) . - Conditioning regimen : Patients receive fludarabine phosphate IV 30 minute day -7 -3 busulfan IV 2 hour within day -15 -10 IV continuously 90 hour day -7 -4 . Patients MRD also receive Methotrexate ( MTX ) Days +1 , +3 , +6 . Patients MUD receive ATG Days -3 -2 MTX Days +1 , +3 +6 . Phase I portion : Cohorts 3-6 patient receive escalate dos busulfan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Allogeneic peripheral blood stem cell transplantation : Patients undergo allogeneic peripheral blood stem cell transplantation day 0 . Patients receive sargramostim ( GM-CSF ) subcutaneously begin day 5 continue blood count recover . - Graft-vs-host disease ( GVHD ) prophylaxis : Patients receive oral tacrolimus twice daily day -1 180 day -1 240 . - Donor lymphocyte infusion ( DLI ) : Patients achieve CR , GVHD , immunosuppressant least 30 day may receive 3 DLIs , least 8 week apart , completion tacrolimus . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis follow : Chronic lymphocytic leukemia prolymphocytic leukemia Chemotherapyrefractory advance disease ≥ 3 prior treatment Chronic myelogenous leukemia Diagnosis base ( 9 ; 22 ) relate ( 9 ; 12 ) cytogenetic abnormality AND characterize elevated WBC count peripheral blood marrow Patients progressive disease imatinib mesylate protein tyrosine kinase inhibitor ; less major cytogenetic fluorescent situ hybridization ( FISH ) complete response ( CR ) minimum 6 month target therapy ; le complete FISH cytogenetic response 12 month target therapy eligible Patients cytogenetic abnormality , ( 9 ; 12 ) , associate aggressive clinical course eligible NonHodgkin 's lymphoma ( NHL ) Hodgkin 's lymphoma Any WHO classification histologic subtype allow Must advance disease define relapse initial CR failure achieve CR OR deem less 30 % likelihood durable response autologous stem cell transplant Refractory lowgrade NHL histology intermediate aggressive large cell mantle cell lymphoma allow Acute myeloid leukemia ( AML ) Highrisk disease first CR ( CR1 ) OR evidence recurrent disease beyond CR1 Highrisk individual require 1 course induction therapy achieve remission ; extramedullary disease presentation ; highrisk cytogenetic abnormality ( abnormality chromosomes 5 , 7 , 2 , trisomy 8 , 3 ) &gt; 2 cytogenetic abnormality Multiple myeloma Myelodysplastic syndrome ( MDS ) Must MDS define WHO criteria &gt; 5 % blast highrisk cytogenetic abnormality ( abnormality chromosomes 5 , 7 , 2 , trisomy 8 , 3 ) Acute lymphoblastic leukemia ( ALL ) Highrisk disease CR1 OR beyond CR1 Highrisk disease include follow : ( 9 ; 22 ) ( 4 ; 11 ) ; WBC &gt; 30,000/mm³ presentation ; nonTcell phenotype ; 30 year age Myelofibrosis/agnogenic myeloid metaplasia Patients must transfusion dependant evidence evolve AML evidence excess blast state marrow failure/fibrosis Myeloproliferative disorder advance disease ( e.g. , progressive spent phase polycythemia vera , myelofibrosis , essential thrombocythemia ) Any follow category donor acceptable* : HLAidentical 1 antigenmismatched sibling ( 5/6 , 6/6 , 8/10 ) donor Minimal serologic typing required class I ( A , B ) ; molecular typing require class II ( DRB1 ) 8/10 match unrelated donor ( MUD ) Molecular analysis HLAA , B , C , DRB1 DQB1 ( 8/10 match ) high resolution typing require 5/6 MUD Molecular analysis HLAA , B , DRB1 require NOTE : *No syngeneic donor PATIENT CHARACTERISTICS : Performance status 02 Bilirubin ≤ 2 time upper limit normal ( ULN ) AST ≤ 2 time ULN Creatinine clearance ≥ 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception DLCO &gt; 60 % symptomatic pulmonary disease LVEF ≥ 50 % MUGA No uncontrolled severe cardiovascular disease , pulmonary disease , infection , opinion treat physician , would make study unreasonably hazardous patient No serious illness would limit survival &lt; 2 year No psychiatric condition would preclude study compliance No uncontrolled diabetes mellitus active serious infection No active second malignancy except nonmelanomatous skin cancer No know hypersensitivity E. coliderived product No HIV positivity PRIOR CONCURRENT THERAPY : See Disease Characteristics More 4 week since prior chemotherapy , radiotherapy , surgery Cranial radiotherapy intrathecal therapy prophylaxis CNS recurrence within past 4 week allow ( highrisk patient )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
</DOC>